Compare ZENV & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZENV | RFL |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.9M | 54.4M |
| IPO Year | 2021 | N/A |
| Metric | ZENV | RFL |
|---|---|---|
| Price | $0.99 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.0K | ★ 188.7K |
| Earning Date | 03-16-2026 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,426,369.00 | $1,029,000.00 |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.80 | ★ 47.63 |
| 52 Week Low | $0.94 | $1.15 |
| 52 Week High | $3.03 | $3.19 |
| Indicator | ZENV | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 33.45 | 40.12 |
| Support Level | $1.05 | $1.21 |
| Resistance Level | $1.13 | $1.29 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 24.30 | 4.44 |
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.